 Dolutegravir is an HIV-1 integrase inhibitor which is marketed as a single tablet Tivicay and in a fixed dose combination tablet with abacavir and lamivudine Triumeq, referred to as TRI. For patients with swallowing difficulties, administration of whole tablets can be problematic and tablets are cut or crushed to ease administration. In addition, if HIV patients develop opportunistic infections, patients can become severely ill and may end up on the intensive care. Patients at the intensive care might not be able to swallow medication. Therefore it is useful to know if it is possible to administer TRI through a different route, like a feeding tube. If TRI can be crushed or dissolved and given through a catheter it is also useful to know if it can be given with drip feed. 